| scholarly article | Q13442814 |
| P50 | author | Gilad Itchaki | Q61188200 |
| P2093 | author name string | Jennifer R Brown | |
| P2860 | cites work | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 |
| Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing | Q58324020 | ||
| Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival | Q80709731 | ||
| Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse | Q85536716 | ||
| The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells | Q86516013 | ||
| Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study | Q86625695 | ||
| PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia | Q89401183 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis | Q26995669 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment | Q28082086 | ||
| Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis | Q28277551 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data | Q31096565 | ||
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
| Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia | Q33419843 | ||
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 | ||
| Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors | Q33566747 | ||
| Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib | Q34009064 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors | Q34067085 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases | Q34355151 | ||
| Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia | Q34418874 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma | Q34534572 | ||
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia | Q34617307 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. | Q35583403 | ||
| Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 | Q35920657 | ||
| Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study | Q35953518 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36253983 | ||
| Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients | Q36273066 | ||
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36337598 | ||
| Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation | Q36368467 | ||
| Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement | Q36368492 | ||
| Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. | Q36437030 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia | Q36550468 | ||
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia | Q36597026 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study | Q36759124 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition | Q36925503 | ||
| Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. | Q37148767 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. | Q37290270 | ||
| FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. | Q37404843 | ||
| Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation | Q37688439 | ||
| Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia | Q37959298 | ||
| Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial | Q38001693 | ||
| New insights into pre-BCR and BCR signalling with relevance to B cell malignancies | Q38123936 | ||
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 | ||
| Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials | Q38656503 | ||
| BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia | Q38729031 | ||
| Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. | Q38765458 | ||
| Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States | Q38792651 | ||
| New treatment approaches in CLL: Challenges and opportunities in the elderly | Q38918639 | ||
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study | Q38956893 | ||
| Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib | Q38974011 | ||
| Current state of hematopoietic cell transplantation in CLL as smart therapies emerge | Q38980975 | ||
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Q39005118 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels | Q39025763 | ||
| Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | Q39028378 | ||
| Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). | Q39154824 | ||
| Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. | Q39407349 | ||
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. | Q39416260 | ||
| Mutations driving CLL and their evolution in progression and relapse | Q39714436 | ||
| Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia | Q40264475 | ||
| Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia | Q40397638 | ||
| Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. | Q40474461 | ||
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri | Q40662825 | ||
| A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. | Q40736899 | ||
| Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia | Q40834193 | ||
| Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes | Q40847547 | ||
| Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. | Q42315534 | ||
| Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib | Q42318090 | ||
| Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. | Q42348711 | ||
| Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib | Q42383009 | ||
| Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia | Q42399825 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. | Q43185847 | ||
| Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma | Q43469341 | ||
| Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. | Q44135101 | ||
| Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells | Q46055970 | ||
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
| Follicular helper T-cell-related lymphomas. | Q48122079 | ||
| Deregulation of NF-κB, ie, a useful PMBL marker | Q48173519 | ||
| Ventricular arrhythmias and sudden death in patients taking ibrutinib | Q48211381 | ||
| Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen. | Q48738934 | ||
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 | ||
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 | ||
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 | ||
| Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 | ||
| P433 | issue | 1 | |
| P921 | main subject | lymphocyte | Q715347 |
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 3-19 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | Therapeutic advances in hematology | Q26842172 |
| P1476 | title | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia | |
| P478 | volume | 9 |
| Q92995778 | Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications |
| Q58609454 | Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis |
| Q92571449 | Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus |
| Q92186292 | Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q89879065 | Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia |
| Q90679839 | Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases |
Search more.